

Development of a CD33-targeted lead antibody for the treatment of AML based on a novel innovative antibody platform technology

Centenaire Biosciences, Inc



| ONCOLOGY | Lead |
|--------------------------|--|
| Product Type | Twin Fc-ICE antibody (Biopharmaceutical) |
| Indication | Acute myeloid leukemia |
| Target | CD33 |
| MoA(Mechanism of Action) | Enhanced antibody-mediated function (ADCC, ADCP and CDC) by engaging innate immune cells with Twin Fc-ICE platform |
| Competitiveness | <ul style="list-style-type: none"> • Innovative Twin Fc-ICE platform for engaging innate immune cells via increased binding to activating Fcγ receptors • Overcoming the limitation of antibody therapeutics • Targeting CD33, a clinically proven target for AML |
| Development Stage | Lead |
| Route of Administration | IV |